The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its ... price cut with the company, along with ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

While the recent positive news in oncology and the acquisition may have... Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46th Annual Global Health Care Conference on June ...

Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46th Annual Global Health Care Conference on June 10, 2025. Lucas Montarce, Lilly executive vice president and chief ...